CoChat
Cited by 104

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Ligand-based design identifies a potent NUPR1 inhibitor exerting anticancer activity via necroptosis

Open access
Santofimia-Castaño, Patricia, Xia, Yi, Lan, Wenjun, Zhou, Zhengwei, Huang, Can, Peng, Ling, Soubeyran, Philippe, Velázquez-Campoy, Adrián, Abián, Olga, Rizzuti, Bruno, Neira, José L., Iovanna, Juan · 2019 · Journal of Clinical Investigation

Abstract

Intrinsically disordered proteins (IDPs) are emerging as attractive drug targets by virtue of their prevalence in various diseases including cancer. Drug development targeting IDPs is challenging because they have dynamical structure features and conventional drug design is not applicable. NUPR1 is an IDP playing an important role in pancreatic cancer. We previously reported that Trifluoperazine (TFP), an antipsychotic agent, was capable of binding to NUPR1 and inhibiting tumors growth. Unfortunately, TFP showed strong central nervous system side-effects. In this work, we undertook a multidisciplinary approach to optimize TFP, based on the synergy of computer modeling, chemical synthesis, and a variety of biophysical, biochemical and biological evaluations. A family of TFP-derived compounds was produced and the most active one, named ZZW-115, showed a dose-dependent tumor regression with no neurological effects and induced cell death mainly by necroptosis. This study opens a new perspective for drug development against IDPs, demonstrating the possibility of successful ligand-based drug design for such challenging targets.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci127223

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 104

Metadata

Authors
Santofimia-Castaño, P., Xia, Y., Lan, W., Zhou, Z., Huang, C., Peng, L., Soubeyran, P., Velázquez-Campoy, A., Abián, O., Rizzuti, B., Neira, J. L., & Iovanna, J.
Venue
Journal of Clinical Investigation
Published
2019-05-13
Volume
129
Issue
6
Pages
2500-2513
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W2932123589
Cited by
104
References
1
FWCI
10.31
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ligand-based design identifies a potent NUPR1 inhibitor exerting anticancer activity via necroptosis. https://app.cochat.ai/papers/10.1172/jci127223
The paper
Santofimia-Castaño, P., Xia, Y., Lan, W., Zhou, Z., Huang, C., Peng, L., Soubeyran, P., Velázquez-Campoy, A., Abián, O., Rizzuti, B., Neira, J. L., & Iovanna, J. (2019). Ligand-based design identifies a potent NUPR1 inhibitor exerting anticancer activity via necroptosis. Journal of Clinical Investigation. https://doi.org/10.1172/jci127223

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.